14th KUMAMOTO AIDS Seminar

Candidates for Best Presentation Award

Presentation No. Presenter Title O-13 Ei Kinai [NCGM] Prevalence and risk factors of bone mineral density abnormalities in Japanese HIV-infected patients O-15 Madoka Koyanagi [Kumamoto Univ.] Synergistic effect of a combination of CTLs response on control of HIV-1 in Japanese individuals carrying HLA-B*35:01 allele associated with rapid disease progression. O-16 Hayato Murakoshi [Kumamoto Univ.] Control of HIV-1 by HIV-1 immunodominant epitope-specific CD8+ T cells in chronically HIV-1-infected Japanese individuals P-01 Kouki Matsuda [Kumamoto Univ.] Inhibition of HIV-1 entry by a tricyclic coumarin GUT-70 P-02 O-35-3B Ryusho Kariya [Kumamoto Univ.] HAMLET and BAMLET induces cell death of Primary Effusion Lymphoma P-03 Hiroki Goto [Kumamoto Univ.] Targeting IL-6 in the crosstalk between HIV-1 infection and primary effusion lymphoma P-04 Eriko Kudo [Kumamoto Univ.] HIV-1 restriction factor, Murr1 (COMMD1), suppresses Toll-like receptor signaling in HIV-1 latently infected cells P-05 Farzana Bhuyan [Kumamoto Univ.] Features of HIV-1 replication in fibrocytes, the recently identified target cells of HIV-1 P-06 O-18-3A Md Abu Osman [Kumamoto Univ.] M-CSF diminishes anti-HIV-1 activity of cytokines including IL-32 P-07 Hesham E. Nasser [Kumamoto Univ.] Phenotypes of fibrocytes, the recently identified HIV-1 host cells P-08 Michihiro Hashimoto [Kumamoto Univ.] The selective activation of anti-inflammatory M2-type macrophages by HIV-1 Nef is mediated by a serine/threonine kinase TAK1 P-09 Kodai Kawano [Kumamoto Univ.] HIV-1 suppresses LINE-1 retrotransposition P-10 O-33-3B Kazuhiko Maeda [Kumamoto Univ.] Role of mammalian TREX-2 component GANP in HIV-1 infection P-11 Kazuaki Monde [Kumamoto Univ.] HERV-K Gag coassembles with HIV-1 Gag via its CA domain and changes morphology of HIV-1 particles to reduce the infectivity P-12 Yusuke Nakano [Kumamoto Univ.] Preferential recognition of monomeric forms of CCR5 by HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1 P-13 Hiromi Terasawa [Kumamoto Univ.] Competitive resistance of a CXCR4-using HIV-1 lacking amino acid substitutions in the V3 loop of gp120 to a CXCR4 inhibitor AMD3100 P-14 Junko S Takeuchi [Kyoto Univ.] Quantification of HIV cell-free and cell-to-cell transmissions based on experimental-mathematical investigations P-15 O-19-3A Kristel Paola Ramirez Valdez [Kumamoto Univ.] Can antibodies contribute to controlling infection with transmitted/founder virus? P-16 Kazuki Tanaka [Kumamoto Univ.] Miniaturization of antibodies against CD4-induced epitope on gp120 P-17 Yasuhiro Maruta [Kumamoto Univ.] Post-attachment neutralization as a mechanism of efficient activities of scFv from anti-V3 monoclonal antibody P-18 O-34-3B Muntasir Alam [Kumamoto Univ.] Effects of Enfuvirtide resistant mutations on the sensitivity to neutralizing antibodies P-19 O-28-3B Shohei Taketomi [Tokyo Medical and Dental Univ.] Structure activity relationship studies on a spacer moiety of small molecular CXCR4 antagonists as potent HIV-1 entry inhibitors P-20 Yuki Hirota [Tokyo Medical and Dental Univ.] Indole-type small CD4 mimic molecules targeting an HIV envelope protein gp120 P-21 Shigeyoshi Harada [NIID] In vitro selection of bifunctional CD4 mimic small compounds (NBD analogues) using bulk and cloned primary isolates P-22 Samatchaya Boonchawalit [Kumamoto Univ.] Analysis of relationships between Maraviroc (MVC) resistant mutations and sensitivity to antibody-mediated neutralization P-23 O-29-3B Masayuki Amano [Kumamoto Univ.] Discovery of small compounds which induce HIV-1 Capsid protein degradation P-24 Tomofumi Nakamura [Kumamoto Univ.] Dynamics of IN multimerization and a potent modulation by allosteric HIV-1 integrase (IN) inhibitors in living cells using bimolecular fluorescence complementation (BiFC) P-25 Joseph R. Campbell [Kumamoto Univ.] Accessing HIV-1 Integrase LEDGF Binding Inhibitors using bimolecular fluorescence complementation (BiFC) P-26 Hiromi Ogata-Aoki [Kumamoto Univ.] Prophylactic administration of Raltegravir alters dynamics of HIVmC dissemination in huPBMC-transplanted NOJ mice P-27 O-31-3B Amber R. Moore [Kumamoto Univ.] Evaluation of HIV-1 reverse transcriptase (RT) heterodimerization within living cells using bimolecular fluorescence complementation (BiFC) P-28 O-30-3B Hironori Hayashi [Kumamoto Univ.] The dimerization inhibition mechanism of darunavir and the dynamics of HIV-1 protease dimerization P-29 O-32-3B Pedro Miguel Salcedo Gomez [Kumamoto Univ.] GRL-04810 and GRL-05010; novel difluoride-containing HIV-1 protease inhibitors (PIs) with potent antiviral activity and favorable penetration across the blood-brain barrier P-30 Manabu Aoki [Kumamoto Health Science Univ.] Novel HIV-1 protease inhibitors, GRL-015, GRL-085, and GRL-097, potently inhibit the replication of multi-PI-resistant HIV-1s P-31 O-27-3A Takayuki Chikata [Kumamoto Univ.] Host-specific adaptation of HIV-1 subtype B in the Japanese population P-32 O-22-3A Xiaoming Sun [Kumamoto Univ.] Presentation of two HLA-A*24:02-restricted overlapping epitopes elicit different patterns of CD8 T cell repertoire and select same escape mutation in HIV-infected patients P-33 O-21-3A Nozomi Kuse [Kumamoto Univ.] Control of HIV-1 by Pol283-8-specific CTLs in HLA-B*51:01+long-term non progressors P-34 Tomohiro Akahoshi [Kumamoto Univ.] Reversion of a CTL escape mutation by escape mutant-specific CTLs P-35 Zhansong Lin [Kumamoto Univ.] Inhibition of human NK cell function by an HLA-Cw*12:02-restricted HIV-1 CTL epitope peptide and its escape mutant peptide P-36 Tran Van Giang [Kumamoto Univ.] Establishment a cohort of chronically treatment-naive patients infected with HIV-1 in Hanoi P-37 O-25-3A Keiko Sakai [Kumamoto Univ.] The lack of a significant impact of HIV-1 Gag replication capacities on patients’ disease outcomes in a chronically infected, treatment-naive Japanese cohort P-38 Mohammad Arif Rahman [Kumamoto Univ.] Effect of protease inhibitor- and integrase inhibitor-resistant mutations on HIV-1-specific CTL recognition P-39 O-24-3A Macdonald Mahiti [Kumamoto Univ.] Differential modulation of Nef-mediated downregulation activity of HLA class I alleles in HIV-1 chronic infection P-40 O-26-3A Stanley C. Meribe [Kumamoto Univ.] Acceleration of disease Progression by a single naturally-arising polymorphism, within functional region of HIV-1 nef P-41 Doreen Kamori [Kumamoto Univ.] HLA-A*02 allelic variants differently influence amino acid polymorphisms in an immunodominant epitope of HIV-1 Vpr P-42 Mako Toyoda [Kumamoto Univ.] Analysis of naturally-occurring polymorphisms of HIV-1 Nef that impair CD4 down-regulation activity P-43 O-20-3A Chihiro Motozono [Kinki Univ.] Molecular basis of a dominant T cell response to an HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:01 P-44 Hiroshi Ishii [NIID] Distinctive phenotype profiles of Env-specific CD8+ T cells in the chronic phase of SIV infection P-45 O-23-3A Koji Watanabe [NCGM] Cross-clade CD8+ T cell responses in chronically HIV-1 clade A/E-infected individuals P-46 Manthana Mitchai [Kumamoto Univ.] HIV infection associated thrombocytopenia : a favourable clinical outcome in HAART therapy patient P-47 O-36-3B Junko Tanuma [NCGM] Stably low prevalence of drug resistant HIV transmission while antiretroviral therapy was scaling up in Southern Vietnam: 2008-2012 P-48 O-37-3B Kazuhiro Matsuoka [Nagoya Medical Center] Cross-Resistance Mutation Patterns in Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine in Clinical Isolates P-49 Mayumi Imahashi [Nagoya Medical Center] Dissociation between insertion/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk: a population-based matched-cohort study in Japan P-50 Takeshi Nishijima [NCGM/ Kumamoto Univ.] Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo P-51 Masahiro Ishikane [NCGM] Acute C hepatitis in Japanese HIV-infected patients in this decade P-52 Daisuke Mizushima [NCGM/ Kumamoto Univ.] Clinical utility of quantitative cytomegalovirus DNA and its kinetics for predicting cytomegalovirus end-organ disease in HIV-infected patients P-53 Fumihide Kanaya [NCGM] Monitoring of bone side effects during maraviroc containing treatment P-54 Masaaki Toyama [Kagoshima Univ.] A tetrahydrotetramethylbenzophenanthridinone derivative selectively inhibits the proliferation of adult T-cell leukemia (ATL) cell lines in vitro P-55 Yohann White [University of the West Indies, Jamaica] Impact of co-infection with human immunodeficiency virus type-1 and human T-cell lymphotropic virus type-1 on the latent HIV-1 reservoir in Jamaican patients with dual infection

Home (Japanese)

Home (English)

Center for AIDS Research HP